Survey of ophthalmology · 2019
Pharmacologic therapy of mycotic keratitis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sahay Pranita, Singhal Deepali, Nagpal Ritu, Maharana Prafulla K, Farid Marjan, Gelman Rachel, Sinha Rajesh, Agarwal Tushar, Titiyal Jeewan S, Sharma Namrata
Аннотация
Mycotic keratitis continues to be an important cause of corneal blindness, especially in tropical and subtropical countries. The prognosis is poor compared with many other forms of keratitis because of the lack of effective antifungal drugs. The currently available antifungal drugs suffer from multiple drawbacks such as poor ocular penetration, unpredictable bioavailability, and adverse effects associated with systemic medications. Over the last decade, several new drugs and drug-delivery systems have been introduced in an attempt to improve the treatment outcomes. Thorough knowledge of the currently available antifungal drugs, their spectrum of action, and associated adverse effects is essential to deal with cases of mycotic keratitis. We discuss the pharmacologic properties and clinical use of the currently available antifungal drugs.